Third, it was found that treating paclitaxel-resistant cervical cancer cell lines with a combination of paclitaxel and PI3K inhibitors led to anti-tumorigenic effects, such as arresting the cell cycle in the S–G2M phase, inducing accumulation of γ-H2AX foci to respond DNA damage and apoptosis and causing decreased migration/invasion. The gene discussed is H2AX; the disease is cervical carcinoma.